(Q37929511)

25 August 2017

1 reference

title

Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes (English)

1 reference

25 August 2017

0 references

Vanita R Aroda

1

1 reference

PubMed ID

21904106

25 August 2017

Mary Beth DeYoung

series ordinal

2

1 reference

PubMed ID

21904106

25 August 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

25 August 2017

Postgraduate Medicine

1 reference

25 August 2017

123

1 reference

25 August 2017

5

1 reference

25 August 2017

228-238

1 reference

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

25 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Glucose Metabolism and Regulation: Beyond Insulin and Glucagon

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Biodegradation and biocompatibility of PLA and PLGA microspheres

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Extended-release intramuscular naltrexone

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Long-acting injectable naltrexone for the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Liraglutide: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Exenatide versus glibenclamide in patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Interventions to enhance patient adherence to medication prescriptions: scientific review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Durability of effects of exenatide treatment on glycemic control, body weight, systolic blood pressure, C-reactive protein, and triglyceride concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

A1C and weight outcomes at 18 months in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

A cohort study of acute pancreatitis in relation to exenatide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2011.09.2479

21 January 2018

Identifiers

DOI

10.3810/PGM.2011.09.2479

1 reference

25 August 2017

1 reference

PubMed ID

21904106